Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6799477 in healthy volunteers and type 2 diabetes patients
NCT02164266Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO6799477 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events at 9 weeks. Started Jun 2014; status: completed.
02
Drugs
RO6799477
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02164266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164266.